Compare Biocon with WYETH - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs WYETH - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

WYETH 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON WYETH BIOCON /
WYETH
 
P/E (TTM) x 31.7 27.7 114.5% View Chart
P/BV x 3.8 5.3 70.7% View Chart
Dividend Yield % 0.3 1.3 20.4%  

Financials

 BIOCON    WYETH
EQUITY SHARE DATA
    BIOCON
Mar-19
WYETH
Mar-13
BIOCON /
WYETH
5-Yr Chart
Click to enlarge
High Rs7071,044 67.7%   
Low Rs554818 67.7%   
Sales per share (Unadj.) Rs91.9298.6 30.8%  
Earnings per share (Unadj.) Rs16.757.2 29.2%  
Cash flow per share (Unadj.) Rs24.258.4 41.4%  
Dividends per share (Unadj.) Rs1.0017.00 5.9%  
Dividend yield (eoy) %0.21.8 8.7%  
Book value per share (Unadj.) Rs101.6249.5 40.7%  
Shares outstanding (eoy) m600.0022.72 2,640.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.93.1 220.0%   
Avg P/E ratio x37.716.3 232.0%  
P/CF ratio (eoy) x26.115.9 163.6%  
Price / Book Value ratio x6.23.7 166.2%  
Dividend payout %6.029.7 20.2%   
Avg Mkt Cap Rs m378,33021,157 1,788.2%   
No. of employees `0006.10.5 1,246.1%   
Total wages/salary Rs m11,653400 2,913.3%   
Avg. sales/employee Rs Th8,994.313,787.4 65.2%   
Avg. wages/employee Rs Th1,900.7813.0 233.8%   
Avg. net profit/employee Rs Th1,635.32,643.3 61.9%   
INCOME DATA
Net Sales Rs m55,1446,783 812.9%  
Other income Rs m1,444353 409.5%   
Total revenues Rs m56,5887,136 793.0%   
Gross profit Rs m15,8831,617 982.1%  
Depreciation Rs m4,47827 16,834.6%   
Interest Rs m7096 12,890.9%   
Profit before tax Rs m12,1401,938 626.5%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m2,123632 335.8%   
Profit after tax Rs m10,0261,301 770.9%  
Gross profit margin %28.823.8 120.8%  
Effective tax rate %17.532.6 53.6%   
Net profit margin %18.219.2 94.8%  
BALANCE SHEET DATA
Current assets Rs m48,2286,984 690.6%   
Current liabilities Rs m30,3762,056 1,477.5%   
Net working cap to sales %32.472.6 44.6%  
Current ratio x1.63.4 46.7%  
Inventory Days Days6899 68.8%  
Debtors Days Days8624 357.2%  
Net fixed assets Rs m64,130244 26,250.5%   
Share capital Rs m3,000227 1,320.4%   
"Free" reserves Rs m57,9805,441 1,065.7%   
Net worth Rs m60,9805,668 1,075.9%   
Long term debt Rs m15,76625 63,064.0%   
Total assets Rs m121,9247,901 1,543.1%  
Interest coverage x18.1353.3 5.1%   
Debt to equity ratio x0.30 5,861.7%  
Sales to assets ratio x0.50.9 52.7%   
Return on assets %8.816.5 53.3%  
Return on equity %16.422.9 71.7%  
Return on capital %16.834.0 49.2%  
Exports to sales %28.10.2 12,888.1%   
Imports to sales %18.936.3 51.9%   
Exports (fob) Rs m15,50615 104,770.3%   
Imports (cif) Rs m10,3992,465 421.8%   
Fx inflow Rs m15,50615 102,013.2%   
Fx outflow Rs m10,3992,677 388.4%   
Net fx Rs m5,107-2,662 -191.8%   
CASH FLOW
From Operations Rs m11,546923 1,250.6%  
From Investments Rs m-7,138317 -2,252.4%  
From Financial Activity Rs m-2,417-481 502.5%  
Net Cashflow Rs m2,103759 277.0%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 51.1 40.3%  
Indian inst/Mut Fund % 8.4 11.3 74.3%  
FIIs % 10.7 7.2 148.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 30.4 65.5%  
Shareholders   109,995 21,978 500.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SUVEN LIFE SCIENCES  NEULAND LABS  PFIZER  TTK HEALTHCARE  SHASUN PHARMA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 296 Points Higher; Coal India, UPL & Hindalco Surge Over 6%(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 10, 2021 (Close)

TRACK BIOCON

BIOCON - GLENMARK PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS